Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses

Abstract : T cells are central to the detrimental alloresponses that develop in autoimmunity and transplantation, with CD28 costimulatory signals being key to T cell activation and proliferation. CTLA4-Ig molecules that bind CD80/86 and inhibit CD28 costimulation offer an alternative immunosuppressive treatment, free from some of the chronic toxicities associated with calcineurin inhibition. However, CD80/86 blockade by CTLA4-Ig also results in the loss of coinhibitory CTLA4 signals that are critical to the regulation of T cell activation. Here, we show that a nonactivating monovalent anti-CD28 that spares CTLA4 signaling is an effective immunosuppressant in a clinically relevant humanized mouse transplant model. We demonstrate that selective CD28 blockade prolongs human skin allograft survival through a mechanism that includes a reduction in the cellular graft infiltrate. Critically, selective CD28 blockade promotes Treg function in vivo and synergizes with adoptive Treg therapy to promote transplant survival. In contrast to CTLA4-Ig treatment, selective CD28 blockade promotes regulation of alloimmune responses and facilitates Treg-based cellular therapy.
Document type :
Journal articles
Complete list of metadatas

Cited literature [41 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02154998
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Thursday, June 13, 2019 - 11:45:46 AM
Last modification on : Friday, June 14, 2019 - 1:59:05 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

  • HAL Id : inserm-02154998, version 1

Collections

Citation

Masaaki Zaitsu, Fadi Issa, Joanna Hester, Bernard Vanhove, Kathryn Wood. Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses. JCI Insight, American Society for Clinical Investigation, 2017. ⟨inserm-02154998⟩

Share

Metrics

Record views

21